pf-956980 has been researched along with Lung-Diseases* in 1 studies
1 other study(ies) available for pf-956980 and Lung-Diseases
| Article | Year |
|---|---|
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.
By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies. Topics: Administration, Cutaneous; Administration, Inhalation; Animals; Anti-Inflammatory Agents; Binding Sites; Crystallography, X-Ray; Dogs; Drug Design; Hepatocytes; Heterocyclic Compounds, 2-Ring; Humans; Indazoles; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinases; Lung Diseases; Mice, Inbred BALB C; Microsomes, Liver; Phosphorylation; Protein Kinase Inhibitors; Rats; Skin Diseases; Solubility | 2017 |